Roche Reports registry Data for Idecabtagene vicleucel in Type 2 diabetes

Roche today announced registry results for idecabtagene vicleucel in patients with type 2 diabetes. The study demonstrated that idecabtagene vicleucel reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of type 2 diabetes and support the continued development of idecabtagene vicleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.